Introduction {#s1}
============

Type 1 diabetes (T1D) is an autoimmune disease characterized by destruction of the insulin-producing β-cells in the pancreatic islets. Although its etiology is not yet understood, strong genetic and environmental components appear to modulate individual disease susceptibility in patients and in animal models [@pone.0085982-Eisenbarth1]. The cytotoxic T lymphocyte antigen-4 gene (*CTLA4*) and the gene encoding CD28 have been mapped to chromosome 2q33. CTLA4 is a glycoprotein receptor expressed on activated T cells and CD28 is involved in the regulation process of the activation of T cells by antigen-presenting cells and subsequent cellular immunity [@pone.0085982-Walunas1]. Based on its role in the regulation of the activation of T cells and T cell and B cell interactions [@pone.0085982-Lane1], *CTLA4* has been considered to be a permissive candidate gene involved in the etiology of autoimmune diseases. A number of common polymorphisms have been reported both in the coding and promoter regions of the *CTLA4* gene. Among them, one common polymorphism in the coding region, which leads to a alanine→threonine substitution at exon 1 (G49A, rs231775) and one located at 3′-UTR (G6230A, C60T, rs3087243) were studied widely for their association with T1D susceptibility.

In the past decade, several association studies have investigated the associations between the *CTLA4* gene and T1D susceptibility. However, these studies yielded conflicting results. Genetic association studies can be problematic to reproduce due to inadequate statistical power, multiple hypothesis testing, population stratification, publication bias, and phenotypic heterogeneity. In addition, with the increased studies in recent years among Caucasian, Asian, and other populations, there is a need to reconcile these data. Therefore, we performed a systematic meta-analysis of published studies to clarify the relationship between *CTLA4* and T1D.

Materials and Methods {#s2}
=====================

Literature search strategy and inclusion criteria {#s2a}
-------------------------------------------------

The literature included in our analysis was selected from PubMed, EMBASE, ISI web of science and Chinese National Knowledge Infrastructure with keywords relating to the relevant genes (e.g. 'cytotoxic T lymphocyte antigen-4' or '*CTLA4*') in combination with words related to T1D (e.g. 'Type 1 diabetes' or 'insulin dependent diabetes mellitus') and 'polymorphism' or 'variation'. Genetic association studies published before the 31 Jan. 2013 on T1D and polymorphisms in the *CTLA4* gene described above were retrieved, and their references were checked to identify other relevant publications. The search was supplemented by reviews of reference lists for all relevant studies and review articles. The major inclusion criteria were (a) original papers containing independent data, (b) case--control or cohort studies and (c) available genotype distribution information or odds ratio (OR) with its 95% confidence interval (OR) with its 95% confidence interval (CI) and P-value. The major reasons for exclusion of studies were (a) overlapping data and (b) case-only studies and review articles.

Data extraction {#s2b}
---------------

Data extraction was performed independently by two reviewers, and differences were resolved by further discussion among all authors. For each included study, the following information was extracted according to a fixed protocol: first author\'s surname, publication year, definition and numbers of cases and controls, diagnostic criterion, frequency of genotypes, source of controls, gender, age at onset, Hardy--Weinberg equilibrium (HWE) status, ethnicity and genotyping method.

Statistical methods {#s2c}
-------------------

The strength of association between polymorphisms of *CTLA4* and T1D risk was assessed by OR with the corresponding 95% CI. The per-allele OR of the risk allele was compared between cases and controls. Then, we examined the association between risk genotype of polymorphisms and T1D susceptibility using dominant and recessive genetic models.

Heterogeneity across individual studies was calculated using the Cochran chi-square Q test followed by subsidiary analysis or by random-effects regression models with restricted maximum likelihood estimation [@pone.0085982-Cochran1]--[@pone.0085982-DerSimonian1]. Random-effects and fixed-effect summary measures were calculated as inverse variance-weighted average of the log OR. The results of random-effects summary were reported in the text because they take into account the variation between studies. In addition, we investigated potential sources of identified heterogeneity among studies by stratifying by ethnic group and the number of cases (≥300 and \<300). Ethnic group was defined as East Asians, Caucasians (i.e. people of European origin) and Middle Eastern (e.g. Iran, Egyptian and Lebanon), Indian and African. The Z test was used to determine the significance of the pooled OR.

We assessed publication bias by using an ancillary procedure attributed to Egger et al. [@pone.0085982-Egger1], which uses a linear regression approach to measure funnel plot asymmetry on the natural logarithm of the OR. The larger the deviation from the funnel curve of each study, the more pronounced the asymmetry will be. The results from small studies tend to scatter widely at the bottom of the graph, with the spread narrowing among larger studies. The significance of the intercept is evaluated using the t test. Sensitivity analysis was performed by removing each individual study in turn from the total and re-analyzing the remainder. This procedure was used to ensure that no individual study was entirely responsible for the combined results. All statistical analyses were carried out with the Stata software version 10.0 (Stata Corporation, College Station, TX, USA). The type I error rate was set at 0.05. All the P-values were for two-sided analysis.

Results {#s3}
=======

Characteristics of included studies {#s3a}
-----------------------------------

The combined search yielded 193 references. 135 articles were excluded because they did not meet the criteria or reported overlapping data ([Figure S1](#pone.0085982.s002){ref-type="supplementary-material"}). Finally, a total of 58 case--control studies were retrieved based on the search criteria for T1D susceptibility related to the *CTLA4* polymorphisms [@pone.0085982-Nistic1]--[@pone.0085982-Mosaad1]. The main study characteristics were summarized in [Table 1](#pone-0085982-t001){ref-type="table"}. There are 51 studies with 10,969 T1D cases and 14,111 controls concerning G49A polymorphism and 15 studies with 22,437 T1D cases and 34,599 controls concerning C60T variation. These two polymorphisms were found to occur in frequencies consistent with HWE in the control populations of the vast majority of the published studies.

10.1371/journal.pone.0085982.t001

###### Characteristics of the studies included in the meta-analysis.

![](pone.0085982.t001){#pone-0085982-t001-1}

  Study                                           Year       Ethnicity                Case                     Control             No. of case/control    Genotyping method    Mean age at onset
  ---------------------------------------------- ------ ------------------- ------------------------ ---------------------------- --------------------- --------------------- -------------------
  Nistico [@pone.0085982-Nistic1]                 1996        Belgian        T1D per NDDG criteria    Non-diabetic participants          483/529         allele-specific PCR          NA
  Donner [@pone.0085982-Donner1]                  1997       American             T1D patients                 Healthy                   293/325                SSCP                 17.9
  Van der Auwera [@pone.0085982-VanderAuwera1]    1997        Belgian        T1D per NDDG criteria             Healthy                   425/530                RFLP                 20.0
  Awata [@pone.0085982-Awata1]                    1998       Japanese             T1D patients                 Healthy                   173/425                 NA                  24.5
  Djilali-Saiah [@pone.0085982-DjilaliSaiah1]     1998        French              T1D patients                 Healthy                   112/100                 NA                  24.9
  Krokowski [@pone.0085982-Krokowski1]            1998        Polish              T1D patients                 Healthy                   192/136         allele-specific PCR          9.5
  Abe [@pone.0085982-Abe1]                        1999       Japanese        T1D per NDDG criteria             Healthy                   111/445                RFLP                  NA
  Hayashi [@pone.0085982-Hayashi1]                1999       Japanese         T1D per ADA criteria             Healthy                   117/141                RFLP                 34.0
  Yanagawa [@pone.0085982-Yanagawa1]              1999       Japanese             T1D patients        Non-diabetic participants          110/200                RFLP                 25.9
  Lee [@pone.0085982-Lee1]                        2000        Chinese        T1D per NDDG criteria    Non-diabetic participants          253/91                 RFLP                  7.1
  Takara [@pone.0085982-Takara1]                  2000       Japanese             T1D patients                 Healthy                   74/107                 RFLP                 21.8
  Ihara [@pone.0085982-Ihara1]                    2001       Japanese        T1D per NDDG criteria    Non-diabetic participants          160/200                SSCP                  7.9
  Kamoun Abid [@pone.0085982-KamounAbid1]         2001       Tunisian             T1D patients                 Healthy                    74/49                 RFLP                 10.3
  Kikuoka [@pone.0085982-Kikuoka1]                2001       Japanese         T1D per WHO criteria    Non-diabetic participants          125/200                RFLP                  NA
  McCormack [@pone.0085982-McCormack1]            2001         Irish              T1D patients                 Healthy                   130/307                 NA                   NA
  Osei-Hyiaman [@pone.0085982-OseiHyiaman1]       2001   Chinese, African    T1D per NDDG criteria             Healthy                   532/621                SSCP                  NA
  Cinek [@pone.0085982-Cinek1]                    2002         Czech          T1D per WHO criteria    Non-diabetic participants          305/289         allele-specific PCR          7.6
  Cosentino [@pone.0085982-Cosentino1]            2002        Italian             T1D patients                 Healthy                    80/85                 RFLP                  NA
  Fajardy [@pone.0085982-Fajardy1]                2002        French          T1D per WHO criteria    Non-diabetic participants          134/273                RFLP                 17.0
  Klitz [@pone.0085982-Klitz1]                    2002      Philippine        T1D per ADA criteria    Non-diabetic participants           90/94          allele-specific PCR          NA
  Ma [@pone.0085982-Ma1]                          2002        Chinese         T1D per ADA criteria             Healthy                    31/36                 RFLP                  NA
  Ongagna [@pone.0085982-Ongagna1]                2002        French          T1D per WHO criteria    Non-diabetic participants           62/84                 RFLP                 13.3
  Wood [@pone.0085982-Wood1]                      2002        German              T1D patients        Non-diabetic participants          176/220                RFLP                  NA
  Bouqbis [@pone.0085982-Bouqbis1]                2003       Moroccan             T1D patients                 Healthy                   118/114              SNaPshot                NA
  Mochizuki [@pone.0085982-Mochizuki1]            2003       Japanese         T1D per ADA criteria    Non-diabetic participants           97/60                 RFLP                  NA
  Haller [@pone.0085982-Haller1]                  2004       Estonian        T1D per ECDC criteria             Healthy                   69/158                 RFLP                  NA
  Ide [@pone.0085982-Ide1]                        2004       Japanese         T1D per ADA criteria             Healthy                   116/114                RFLP                 22.0
  Liang [@pone.0085982-Liang1]                    2004       Japanese         T1D per ADA criteria     Normal glucose tolerance           29/40                 RFLP                 25.3
  Zalloua [@pone.0085982-Zalloua1]                2004       Lebanese             T1D patients                 Healthy                   190/96          allele-specific PCR          8.9
  Caputo [@pone.0085982-Caputo1]                  2005      Argentinean       T1D per WHO criteria             Healthy                   123/168                RFLP                 15.0
  Mojtahedi [@pone.0085982-Mojtahedi1]            2005        Iranian        T1D per NDDG criteria             Healthy                   109/331                SSCP                 16.4
  Zhernakova [@pone.0085982-Zhernakova1]          2005         Dutch                 IS-PAD                    Healthy                   350/900               TaqMan                17.0
  Ahmedov [@pone.0085982-Ahmedov1]                2006         Azeri          T1D per WHO criteria    Non-diabetic participants          160/271                SSCP                  9.1
  Baniasadi [@pone.0085982-Baniasadi1]            2006        Indian          T1D per ADA criteria             Healthy                   130/180                RFLP                 15.4
  Kanazawa [@pone.0085982-Kanazawa1]              2006       Japanese             T1D patients         Normal glucose tolerance           71/39                 RFLP                 35.4
  Ikegami [@pone.0085982-Ikegami1]                2006       Japanese             T1D patients        Non-diabetic participants          769/723               Invader               27.3
  Haller [@pone.0085982-Haller2]                  2007       Estonian        T1D per ECDCD criteria            Healthy                   70/252                 RFLP                 24.3
  Howson [@pone.0085982-Howson1]                  2007        British             T1D patients        Non-diabetic participants         4066/6866              TaqMan                 7.5
  Butty [@pone.0085982-Butty1]                    2008       American             T1D patients        Normoglycemic participants         224/343               TaqMan                 NA
  Kawasaki [@pone.0085982-Kawasaki1]              2008       Japanese         T1D per WHO criteria             Healthy                   91/369                 RFLP                  NA
  Saleh [@pone.0085982-Saleh1]                    2008       Egyptian             T1D patients                 Healthy                   396/396                SSCP                  6.7
  Smyth [@pone.0085982-Smyth1]                    2008        British             T1D patients                 Healthy                  5253/9161              TaqMan                 7.5
  Balic [@pone.0085982-Balic1]                    2009        Chilean         T1D per ADA criteria             Healthy                   300/310                RFLP                  8.9
  Douroudis [@pone.0085982-Douroudis1]            2009   Estonian, Finnish    T1D per WHO criteria             Healthy                   574/955               TaqMan                 NA
  Jin [@pone.0085982-Jin1]                        2009        Chinese         T1D per WHO criteria             Healthy                   413/476                RFLP                 17.0
  Jung [@pone.0085982-Jung1]                      2009        Korean          T1D per WHO criteria             Healthy                   176/90                 RFLP                  7.5
  Korolija [@pone.0085982-Korolija1]              2009       Croatian             T1D patients                 Healthy                   102/193                RFLP                 11.5
  Lemos [@pone.0085982-Lemos1]                    2009      Portuguese            T1D patients                 Healthy                   207/249                RFLP                 16.1
  Momin [@pone.0085982-Momin1]                    2009        Chilean         T1D per ADA criteria             Healthy                   261/280                RFLP                  8.2
  Benmansour [@pone.0085982-Benmansour1]          2010       Tunisian             T1D patients         Normal glucose tolerance          228/193                RFLP                 15.7
  Klinker [@pone.0085982-Klinker1]                2010        Finnish             T1D patients        Normoglycemic participants        591/1538               TaqMan                26.0
  Howson [@pone.0085982-Howson2]                  2011        British         T1D per WHO criteria    Normoglycemic participants        928/2043               TaqMan                33.3
  Philip [@pone.0085982-Philip1]                  2011        Indian              T1D patients                 Healthy                    53/53                 RFLP                  NA
  Plagnol [@pone.0085982-Plagnol1]                2011        British             T1D patients                 Healthy                 8506/10596          Affymetrix chip            8.0
  Reddy [@pone.0085982-Reddy1]                    2011       American         T1D per ADA criteria             Healthy                  1434/1864              TaqMan                 NA
  Wafai [@pone.0085982-EiWafai1]                  2011       Lebanese         T1D per ADA criteria             Healthy                    39/46                 RFLP                  8.9
  Horie [@pone.0085982-Horie1]                    2012       Japanese             T1D patients        Normoglycemic participants         134/222                RFLP                  NA
  Mosaad [@pone.0085982-Mosaad1]                  2012       Egyptian         T1D per ADA criteria             Healthy                   104/78                 RFLP                  8.2

NA: Not Available, WHO: World Health Organization, ADA: American Diabetes Association, ECDC: Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, IS-PAD: International Society of Paediatric and Adolescent Diabetes.

Association of CTLA4 G49A polymorphism and T1D {#s3b}
----------------------------------------------

Overall, there was evidence of an association between the increased risk of T1D and the variant in different genetic models when all the eligible studies were pooled into the meta-analysis. Using random effect model, the summary per-allele OR of the G variant for T1D was 1.42 \[95% CI: 1.31--1.53; *P*(Z)\<10^−5^; *P*(Q)\<10^−5^; [Figure 1](#pone-0085982-g001){ref-type="fig"}\], with corresponding results under dominant and recessive genetic models of 1.48 \[95% CI: 1.31--1.66; *P*(Z)\<10^−5^; *P*(Q)\<10^−5^ \] and 1.68 \[95% CI: 1.47--1.91; *P*(Z)\<10^−5^; *P*(Q)\<10^−5^\], respectively.

![Forest plot from the meta-analysis of type 1 diabetes risk and *CTLA4* G49A polymorphism.](pone.0085982.g001){#pone-0085982-g001}

In the stratified analysis by ethnicity, significantly increased risks were found among East Asian populations \[G allele: OR = 1.47, 95% CI: 1.28--1.69; dominant model: OR = 1.65, 95% CI: 1.29--2.11; recessive model: OR = 1.65, 95% CI: 1.35--2.02\] and Caucasian populations \[G allele: OR = 1.23, 95% CI: 1.20--1.49; dominant model: OR = 1.31, 95% CI: 1.14--1.49; recessive model: OR = 1.68, 95% CI: 1.37--2.06\]. Similar significant associations were also observed for Middle Eastern population \[G allele: OR = 1.50, 95% CI: 1.24--1.80; dominant model: OR = 1.62, 95% CI: 1.15--2.29; recessive model: OR = 1.93, 95% CI: 1.26--2.96\]. However, no significant associations were detected among Indian and African populations ([Table 2](#pone-0085982-t002){ref-type="table"}). Subsidiary analyses of sample size yielded a per-allele OR for small studies of 1.52 (95% CI: 1.34--1.72) and for large studies of 1.30 (95% CI: 1.19--1.42).

10.1371/journal.pone.0085982.t002

###### Meta-analysis of the *CTLA-4* G49A polymorphism on type 1 diabetes risk.

![](pone.0085982.t002){#pone-0085982-t002-2}

  Sub-group analysis    No. of cases/controls   G allele vs. A allele   Dominant model   Recessive model                                                                            
  -------------------- ----------------------- ----------------------- ---------------- ----------------- -------------------- ---------- ---------- ------------------- ---------- ----------
  Total                      10969/14111          1.42 (1.31--1.53)        \<10^−5^         \<10^−5^       1.48 (1.31--1.66)    \<10^−5^   \<10^−5^   1.68 (1.47--1.91)   \<10^−5^   \<10^−5^
  Ethnicity                                                                                                                                                                         
  East Asians                 3430/4453           1.47 (1.28--1.69)        \<10^−5^         \<10^−5^       1.65 (1.29--2.11)    \<10^−4^    0.008     1.66 (1.35--2.02)   \<10^−5^    0.0009
  Caucasians                  5756/7650           1.23 (1.20--1.49)        \<10^−5^         \<10^−5^       1.31 (1.14--1.49)    \<10^−4^    0.002     1.68 (1.37--2.06)   \<10^−5^   \<10^−5^
  Middle Eastern              1226/1411           1.50 (1.24--1.80)        \<10^−4^           0.05         1.62 (1.15--2.29)     0.006      0.0007    1.93 (1.26--2.96)    0.003       0.07
  African                      374/364            1.31 (0.89--1.93)          0.17             0.001        1.43 (0.84--2.44)      0.18       0.11     1.31 (0.61--2.82)     0.49       0.12
  Indian                       183/233            2.24 (0.52--9.69)          0.28             0.08         3.94 (0.33--47.54)     0.28     \<10^−4^   1.89 (0.48--7.41)     0.36       0.02
  Sample size                                                                                                                                                                       
  Small                       4224/6368           1.52 (1.34--1.72)        \<10^−5^         \<10^−4^       1.58 (1.32--1.88)    \<10^−5^   \<10^−5^   1.77 (1.46--2.16)   \<10^−5^   \<10^−5^
  Large                       6745/7743           1.30 (1.19--1.42)        \<10^−5^         \<10^−5^       1.39 (1.20--1.61)    \<10^−4^    0.001     1.58 (1.38--1.82)   \<10^−5^     0.09

Association of CTLA4 C60T polymorphism and T1D {#s3c}
----------------------------------------------

In the overall analysis, the C60T polymorphism of *CTLA4* was significantly associated with elevated T1D risk with a per-allele OR of 1.23 \[95% CI: 1.18--1.29; *P*(Z)\<10^−5^; *P*(Q) = 0.05; [Figure 2](#pone-0085982-g002){ref-type="fig"}\]. Significant associations were also found under dominant \[OR = 1.31; 95% CI: 1.16--1.47; *P*(Z)\<10^−5^; *P*(Q) = 0.11\] and recessive \[OR = 1.32; 95% CI: 1.19--1.43; *P*(Z)\<10^−5^; *P*(Q) = 0.06\] genetic model.

![Forest plot from the meta-analysis of type 1 diabetes risk and *CTLA4* C60T polymorphism.](pone.0085982.g002){#pone-0085982-g002}

When studies were stratified for ethnicity, significant risks were found among Caucasians in all genetic models \[C allele: OR = 1.21, 95% CI: 1.18--1.25; dominant model: OR = 1.31, 95% CI: 1.20--1.44; recessive model: OR = 1.24, 95% CI: 1.18--1.31\]. Similar results were also found in the Middle Eastern populations and Indians with a per-allele OR of 1.67 (95% CI: 1.21--2.29) and 1.41 (95% CI: 1.02--1.94), respectively. Only marginal significant results were detected for East Asians with per-allele OR of 1.33 (95% CI: 1.03--1.71). In the stratified analysis by sample size, significant associations were detected in both large and small studies ([Table 3](#pone-0085982-t003){ref-type="table"}).

10.1371/journal.pone.0085982.t003

###### Meta-analysis of the *CTLA-4* C60T polymorphism on type 1 diabetes risk.

![](pone.0085982.t003){#pone-0085982-t003-3}

  Sub-group analysis    No. of cases/controls   C allele vs. T allele   Dominant model   Recessive model                                                                       
  -------------------- ----------------------- ----------------------- ---------------- ----------------- ------------------- ---------- ------ ------------------- ---------- ------
  Total                      22437/34599          1.23 (1.18--1.29)        \<10^−5^           0.05         1.31 (1.16--1.47)   \<10^−5^   0.11   1.32 (1.19--1.43)   \<10^−5^   0.06
  Ethnicity                                                                                                                                                                    
  East Asians                 1487/1821           1.33 (1.03--1.71)          0.03             0.009        1.18 (0.58--2.43)     0.65     0.06   1.44 (1.00--2.03)     0.05     0.02
  Caucasians                 20592/32405          1.21 (1.18--1.25)        \<10^−5^           0.58         1.31 (1.20--1.44)   \<10^−5^   0.26   1.24 (1.18--1.31)   \<10^−5^   0.43
  Middle Eastern               228/193            1.67 (1.21--2.29)         0.002              NA          1.63 (1.10--2.42)     0.01      NA    2.37 (1.18--4.76)     0.01      NA
  Indian                       130/180            1.41 (1.02--1.94)          0.04              NA          1.74 (1.06--2.87)     0.03      NA    1.34 (0.78--2.33)     0.29      NA
  Sample size                                                                                                                                                                  
  Small                       2226/3680           1.35 (1.21--1.50)        \<10^−5^           0.15         1.39 (1.04--1.86)     0.02     0.09   1.51 (1.30--1.75)   \<10^−5^   0.34
  Large                      20211/30919          1.21 (1.17--1.25)        \<10^−5^           0.25         1.34 (1.23--1.46)   \<10^−5^   0.21   1.22 (1.16--1.29)   \<10^−5^   0.47

NA: not available.

Haplotype analysis {#s3d}
------------------

The linkage disequilibrium (LD) analysis revealed a tight LD between the G49A and C60T sites with D′ score of 0.95. Haplotype analyses between 49G\>A, and C60T polymorphisms were performed in the 4 studies, involving 2242 cases and 2581 controls. Three prevalent haplotypes ([Table S1](#pone.0085982.s005){ref-type="supplementary-material"}), which represent more than 95% of the haplotypes among those studied at the CTLA4 loci (49G\>A, C60T), were detected both in affected and unaffected subjects. The AT haplotype was significantly associated with decreased diabetes risk in the overall analysis (OR = 0.87, 95% CI: 0.77--0.98, P = 0.03). In addition, the frequency of GC haplotype (OR = 1.12, 95% CI: 0.98--1.28, P = 0.10) was also higher in diabetes patients compared with controls.

Sensitivity analyses and publication bias {#s3e}
-----------------------------------------

Sensitivity analysis indicated that no single study influenced the pooled OR qualitatively, suggesting that the results of this meta-analysis are stable (data not shown). A funnel plot of these included studies suggested a possibility of the preferential publication of positive findings in smaller studies for G49A polymorphism of *CTLA4* (Begg test, P = 0.001; Egger test, P = 0.0002; [Figure S2](#pone.0085982.s003){ref-type="supplementary-material"}). The Duval and Tweedie nonparametric "trim and fill" method was used to adjust for publication bias. Meta-analysis with and without "trim and fill" method did not draw different conclusion (data not shown), indicating that our results were statistically robust. The shape of the funnel plots seemed symmetrical for *CTLA4* C60T polymorphism, suggesting that no bias from selected studies have been included ([Figure S3](#pone.0085982.s004){ref-type="supplementary-material"}). The statistical results still did not show publication bias (Begg test, P = 0.32; Egger test, P = 0.18).

Discussion {#s4}
==========

Large sample and unbiased epidemiological studies of predisposition genes polymorphisms could provide insight to etiology of diseases. This is the most comprehensive meta-analysis examined the *CTLA4* polymorphisms and the relationship to susceptibility for T1D. Its strength was based on the accumulation of published data giving greater information to detect significant differences. In total, the meta-analysis involved 58 studies for T1D which provided 30,734 cases and 40,754 controls.

Our results demonstrated that the G49A and C60T polymorphism of *CTLA4* is a risk factor for developing T1D. In the stratified analysis by ethnicity, significant associations were found in Caucasians and Middle Eastern population for the two polymorphisms in all genetic models. Significant associations were detected among East Asians for G49A polymorphism; while no associations were found for C60T polymorphism. Among Indian population, only marginal significant associations were detected for C60T polymorphism. No associations were found in Africans. The reasons that the same polymorphism plays a different role in different ethnic populations or across different studies may arise from many aspects. Firstly, T1D is a complex disease and genetic heterogeneity exists in different populations. Whole genome linkage studies on T1D have confirmed this genetic heterogeneity [@pone.0085982-Villano1]. Secondly, clinical heterogeneity may also explain the discrepancy. Potential contribution of differences in patient populations (e.g., age and years from onset, female proportion, disease severity...) might cause different results. Thirdly, population structure difference may also contribute to the discrepancy. Different populations often have different LD patterns. The same polymorphism plays a different role in disease susceptibility in different ethnic populations, implicating that this polymorphism might not be a causal variant. The fact is that this polymorphism may be in LD with a nearby causal variant in one ethnic population but not in another. Moreover, the difference might come from type I error. Therefore, additional studies are needed to further validate ethnic difference of the effect of these polymorphisms on T1D risk Therefore, additional studies are warranted to further validate ethnic difference in the effect of these polymorphisms on T1D risk.

An important source of bias in every meta-analysis is related to the studies that have been published and thus can be included in the analysis. Nevertheless in our meta-analysis, we included many studies with negative findings. Although the funnel plot for G49A polymorphism is not symmetric, the overall results of different ethnic groups are concordant, indicating that this bias cannot affect the final result. On the other hand, funnel plot asymmetry is not always caused by publication bias. True heterogeneity may also lead to funnel plot asymmetry. For example, significant difference may be seen only in high-risk individuals, and these high-risk people are usually more likely to be included in small studies. This is particularly true in our meta-analysis because the majority of the significant associations have been observed among the studies with small sample size. Language bias or citation bias also could be an important source in this group of studies, meaning that the studies without significant findings are preferentially published in languages other than English and less likely to be cited in other articles. Finally, it is possible that an asymmetrical funnel plot arises simply by chance.

The heterogeneity of OR is high in our data, especially in the studies for African and Indian populations, based on a small number of individuals. Nevertheless, the total number of subjects included in this part of the analysis comprises the largest sample size so far. Future studies including larger numbers of Africans and Indians are necessary to clarify the consistency of findings across ethnic groups. Another possible source of heterogeneity is difference in age at onset of T1D: early or late onset. Unfortunately, it was not possible to tease out this association because the breakdown of the two types was not consistently reported.

A number of factors predict T1D, however, detailed pathogenesis mechanisms of T1D remain a matter of speculation. Polymorphisms of the *CTLA4* gene have been shown to confer susceptibility to several autoimmune diseases, due to its role in the down-regulation of the activated immune response [@pone.0085982-Kouki1]. The 49 G/G genotype of the *CTLA4* gene was associated with reduced inhibitory function of cytotoxic T-lymphocyte antigen 4 [@pone.0085982-Kouki1]. In addition, it is proposed that a reduced function of CTLA4 associated with the C allele of C60T polymorphism allows T cells to be more hyperactive and to respond to peripheral antigens to a greater degree than individuals carrying the T/T genotype, which is associated with autoimmune disease protection and increased peripheral tolerance [@pone.0085982-Ueda1], [@pone.0085982-Atabani1]. Association studies and functional data along with our meta-analysis suggest that G49A and C60T polymorphisms of *CTLA4* are risk factors for developing T1D.

Several meta-analyses addressing the same theme have been recently published [@pone.0085982-Chen1]--[@pone.0085982-Tang1]. However, Chen et al. and Si et al. mainly focused on the G49A polymorphism without assessing the relationship between *CTLA4* C60T polymorphism and T1D [@pone.0085982-Chen1], [@pone.0085982-Si1]. Furthermore, the results reported by Tang et al. were believed to be not entirely credible for insufficient literature identification and overlapping samples [@pone.0085982-Tang1], [@pone.0085982-Chang1]. Compared to those previous meta-analyses, the present study has considered more studies from the literature. In addition, we also investigated the two common variants on *CTLA4* gene and genetic susceptibility to T1D. Furthermore, we also explored whether the *CTLA4* gene haplotypes were associated with T1D risk. Our results also suggest the importance of including a haplotype-based approach to assess genetic associations. Haplotype-based case--control studies are warranted to confirm our findings in the future.

In summary, this meta-analysis showed that the *CTLA4* G49A and C60T polymorphism was significantly associated with increased risk of T1D, particularly in Caucasian and Middle Eastern population. While the CTLA4 G49A and C60T polymorphisms are significantly associated with increased risk of T1D, larger cohorts of Indian and African subjects are needed to test the effect of these SNPs in these populations.
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